Mustang Bio announced Monday safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer.
THOR Industries, Inc. (NYSE:THO) today announced that its Board of Directors approved, at its October 12, 2022 meeting, an increase in the amount of THOR's regular quarterly dividend to $0.45 per share